← Back to Clinical Trials
Recruiting NCT03375619

Long-term Follow-up Study of Patients Receiving CAR-T Cells

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Chronic Lymphocytic Leukemia
Sponsor Medical College of Wisconsin
Study Type OBSERVATIONAL
Phase N/A
Enrollment 500
Sex ALL
Min Age 18 Years
Max Age 80 Years
Start Date 2017-12-01
Completion 2035-01-01
Interventions
Long-Term Follow-Up of Participants who Received CAR-T cells

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This protocol is designed as a long-term follow-up study of participants who will receive CAR-T cells as part of a clinical trial at the Medical College of Wisconsin/ Froedtert Hospital. The clinical trials include the following: Phase 1 Study of CAR-20/19-T Cells in Patients with Relapsed Refractory B Cell Malignancies (NCT03019055); Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma (NCT05976555); CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies (NCT05094206); LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies (NCT05990465); CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies (NCT04186520)

Eligibility Criteria

Inclusion Criteria: * All participants who enrolled in a CAR-T study at Froedtert Hospital \& the Medical College of Wisconsin. Exclusion Criteria: * There are no exclusion criteria for this study.

Related Trials

VIEW ON CLINICALTRIALS.GOV ↗ MORE CHRONIC LYMPHOCYTIC LEUKEMIA TRIALS
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}